AstraZeneca: submits application for Tagrisso in Japan.
(CercleFinance.com) - AstraZeneca said on Monday that it has made a regulatory submission for Tagrisso in first-line EGFR-mutated non-small cell lung cancer in Japan.
The drugmaker has filled a supplemental new drug application to Japan's Pharmaceuticals and Medical Devices Agency for the use of Tagrisso (osimertinib) for the treatment of patients with inoperable or recurrent EGFR mutation-positive non-small cell lung cancer (NSCLC).
The filing is based on data from a Phase III trial that showed that Tagrisso significantly improved progression-free survival compared to current treatments.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The drugmaker has filled a supplemental new drug application to Japan's Pharmaceuticals and Medical Devices Agency for the use of Tagrisso (osimertinib) for the treatment of patients with inoperable or recurrent EGFR mutation-positive non-small cell lung cancer (NSCLC).
The filing is based on data from a Phase III trial that showed that Tagrisso significantly improved progression-free survival compared to current treatments.
Copyright (c) 2017 CercleFinance.com. All rights reserved.